Navigation Links
Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms
Date:8/21/2014

BURLINGTON, Mass., Aug. 21, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of COPD,  physicians in Brazil and Mexico manage to follow clinical guidelines and commonly prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist (LAMA)- containing regimens, although they do so within current severe cost/coverage constraints. Therefore, new brands of LABA/LAMA fixed-dose combinations (FDCs) that are expected to launch in these countries—which will considerably expand the chronic obstructive pulmonary disease (COPD) market—will compete with well-established marketed therapies, especially the twice-daily LABA/ inhaled corticosteroids (ICS) FDCs. New LABA/LAMA FDCs will also compete with recently launched once-daily Relvar/Relvare (GlaxoSmithKline/Theravance). According to payers, improvements in dosing and delivery of new FDCs of current drugs/drug classes are important but may not be enough to justify a premium price over comparator drugs or its separate components.

Other key findings from the Emerging Markets Physician and Payer Forum report entitled Positioning of Current and Emerging Agents for COPD: Physician and Payer Perspectives on the Prescribing and Patient Access Landscape in Brazil and Mexico include:

  • Factors impacting formulary inclusion: In Brazil, CONITEC (Brazil's HTA agency) is restricting the incorporation of new COPD drugs in the coverage offered by the public healthcare system. Demonstration of superior comparative clinical and economic benefit, preferably using local data, is crucial to formulary inclusion.
  • Exclusion of key agents: In Mexico, although th
    '/>"/>

SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema
2. Globavir Seeking Approval and Launch of Novel Ebola Treatment Before Year End
3. The Impact of Genericization in the Unipolar Depression Market Will be Tempered by the Continued Uptake of Novel Antidepressants and Antipsychotics
4. Charleston Laboratories and Daiichi Sankyo Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US
5. FDA Grants Fast Track Designation to CTI BioPharmas Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
6. Daiichi Sankyo and Charleston Laboratories Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US
7. Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer
8. Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology
9. Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide
10. Synthetic Biologics Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference
11. ViaCyte Files Investigational New Drug Application and Device Master File with FDA for Novel Cell Replacement Therapy Product Candidate Designed to Treat Patients with Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... support to healthcare providers for behavioral health and ... secured $30 million in equity financing from new ... Drosos , President and Chief Executive Officer. ... and development of Assurex Health,s GeneSight ® ...
(Date:12/24/2014)... 2014 In response to urgent requests from the Deputy ... Sierra Leone , Direct Relief delivered two 10-bed medical ... treatment of local health workers who contract Ebola while fighting ... care center was constructed for foreign health care workers who ... for local Sierra Leonean health workers. With ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
... Switzerland, Jan. 9 ESBATech AG, a leading developer ... of the Phase I/IIa clinical development of its ... This double-blind, randomized, placebo-controlled Phase I/IIa clinical study ... efficacy on pain with ESBA105 applied locally via ...
... transplantation to be Quark,s second indication with ... Calif., Jan. 8 Quark Pharmaceuticals, Inc., ... novel RNA interference (RNAi)-based therapeutics, today announced ... its Phase I/II clinical trial evaluating its ...
Cached Medicine Technology:ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 2ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 3ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 4Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 2Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 3Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 4
(Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International ... after an 8 year battle with breast cancer. ... in her home in Woodland Hills California after an ... , As the founder and volunteer President ... and championed many of today's greatest breakthroughs in restoring ...
(Date:12/25/2014)... 25, 2014 Recently, LunaDress.co.uk has updated its blog ... related accessories. Now, all of the models at LunaDress.co.uk come with ... groom lifts the wedding veil can turn out to be a ... A wedding veil can always bring surprise to a wedding. On ... how to choose veils for a big day . , ...
(Date:12/25/2014)... (HealthDay News) -- The risk of burns from fires ... need to be extra cautious, an expert says. ... significant increase in patients coming in with burns," said ... Volunteer Firefighters Burn Center of Stony Brook University Hospital ... of joy, but if not careful, could quickly turn ...
(Date:12/25/2014)... News) -- Among early stage breast cancer patients who ... one percent will eventually develop leukemia as a result ... finding comes from a review of more than 20,000 ... it suggests that the risk for developing treatment-related leukemia, ... thought. "The frequency of bone marrow cancers such ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... offers formulas of essential prenatal ... ... Mission Pharmacal today announced,the launch of the CitraNatal(TM) family of ... of essential vitamins,and minerals for women prior to conception, throughout ...
... an,entrepreneur trained in Pilates, is bringing the latest Pilates ... Element Pilates.,Ilitch,s version of the innovative barre workout is ... and dance exercises,in rapid sequence to tone and transform ... any other studios in the area. According to ...
... on Cold and ... ... a division of,American Scientific Resources (Pink Sheets: ASFX), today announced the,launch ... world, now available at Walgreens Stores,nationwide and online at http://www.kidzmed.com ...
... health care system is one of only five organizations ... DIEGO, Nov. 20 President,George W. Bush and Commerce ... five organizations to receive the 2007 Malcolm,Baldrige National Quality ... performance excellence. (Photo: http://www.newscom.com/cgi-bin/prnh/20071120/DC07985-a ...
... Jewelers returns to national campaign for fourth year to support ... in communities everywhere., AKRON, Ohio, Nov. 20 Kay ... off its annual Thanks and Giving,campaign. This is the fourth ... has partnered with St. Jude in fundraising campaigns. Thanks ...
... Eularis WHAT: Presentation on Marketing Return: What can be ... WHEN: 26 November 2007 at 2:30 p.m. GMT, WHERE: Pharmaceutical ... ... and LONDON, Nov. 20 Dr. Andree Bates,president of the pharmaceutical analytics company ...
Cached Medicine News:Health News:Mission Pharmacal Launches CitraNatal(TM) Prescription Prenatal Vitamin Line 2Health News:Ilitch Brings New Brand of Pilates to Metro Detroit With Opening of Studio in West Bloomfield 2Health News:Ilitch Brings New Brand of Pilates to Metro Detroit With Opening of Studio in West Bloomfield 3Health News:World's First Non-Contact Thermometer for Children Now Available at Walgreens Nationwide 2Health News:World's First Non-Contact Thermometer for Children Now Available at Walgreens Nationwide 3Health News:Sharp HealthCare Receives 2007 Presidential Award for Quality and Performance Excellence 2Health News:Sharp HealthCare Receives 2007 Presidential Award for Quality and Performance Excellence 3Health News:Kay Jewelers Joins St. Jude Children's Research Hospital(R) to Kick Off Fourth Annual Thanks and Giving(R) Campaign 2Health News:Kay Jewelers Joins St. Jude Children's Research Hospital(R) to Kick Off Fourth Annual Thanks and Giving(R) Campaign 3Health News:MEDIA ALERT: Eularis to Address Marketing Return at Pharmaceutical Marketing Society Half-day Conference: ROI or RIP? 2
MISTY OX® Gas Injection Nebulizer (GIN)...
... OMNI~NEB delivers breakthrough continuous low-flow ... and precise nozzle technology allows for ... with or without Heliox). OMNI~NEB takes ... in both routine and critical care ...
... Raindrop® medication nebulizer achieves optimum lung penetration ... size range is 1.04-1.10 µ at 6-8 ... air outlet., ,As the world leader ... providers the assurance of proven technology by ...
Reliable and Affordable. The Schuco 3000 Nebulizer by Allied has been designed to offer a compact style that provides worry-free affordable nebulizer therapy....
Medicine Products: